A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Abstract Multiple myeloma (MM) is a heterogeneous haematological disease that remains clinically challenging. Increased activity of the epigenetic silencer EZH2 is a common feature in patients with poor prognosis. Previous findings have demonstrated that metabolic profiles can be sensitive markers f...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-02-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-021-03447-8 |